These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33184267)

  • 1. Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration.
    Luo B; Zhan Y; Luo M; Dong H; Liu J; Lin Y; Zhang J; Wang G; Verhoeyen E; Zhang Y; Zhang H
    Cell Death Dis; 2020 Nov; 11(11):973. PubMed ID: 33184267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy.
    Lee J; Le QV; Yang G; Oh YK
    Biomaterials; 2019 Oct; 218():119359. PubMed ID: 31349094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 blockade augments humoral immunity through ICOS-mediated CD4
    Zhang M; Xia L; Yang Y; Liu S; Ji P; Wang S; Chen Y; Liu Z; Zhang Y; Lu S; Wang Y
    Int Immunopharmacol; 2019 Jan; 66():127-138. PubMed ID: 30448635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors That Govern the Induction of Long-Lived Antibody Responses.
    Chackerian B; Peabody DS
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31936163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
    Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
    Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Lived Plasma Cells Secrete High-Affinity Antibodies Responding to a T-Dependent Immunization in a Teleost Fish.
    Wu L; Fu S; Yin X; Guo Z; Wang A; Ye J
    Front Immunol; 2019; 10():2324. PubMed ID: 31632403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
    Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
    Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human
    Burova E; Hermann A; Waite J; Potocky T; Lai V; Hong S; Liu M; Allbritton O; Woodruff A; Wu Q; D'Orvilliers A; Garnova E; Rafique A; Poueymirou W; Martin J; Huang T; Skokos D; Kantrowitz J; Popke J; Mohrs M; MacDonald D; Ioffe E; Olson W; Lowy I; Murphy A; Thurston G
    Mol Cancer Ther; 2017 May; 16(5):861-870. PubMed ID: 28265006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
    Friedman J; Moore EC; Zolkind P; Robbins Y; Clavijo PE; Sun L; Greene S; Morisada MV; Mydlarz WK; Schmitt N; Hodge JW; Schreiber H; Van Waes C; Uppaluri R; Allen C
    Clin Cancer Res; 2020 Feb; 26(3):679-689. PubMed ID: 31645352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
    Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
    Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells.
    Jung IY; Kim YY; Yu HS; Lee M; Kim S; Lee J
    Cancer Res; 2018 Aug; 78(16):4692-4703. PubMed ID: 29967261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes.
    Luo XM; Maarschalk E; O'Connell RM; Wang P; Yang L; Baltimore D
    Blood; 2009 Feb; 113(7):1422-31. PubMed ID: 19059876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering PD-1-Presenting Platelets for Cancer Immunotherapy.
    Zhang X; Wang J; Chen Z; Hu Q; Wang C; Yan J; Dotti G; Huang P; Gu Z
    Nano Lett; 2018 Sep; 18(9):5716-5725. PubMed ID: 30063143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splenic Long-Lived Plasma Cells Promote the Development of Follicular Helper T Cells during Autoimmune Responses.
    Jang E; Cho WS; Oh YK; Cho ML; Kim JM; Paik DJ; Youn J
    J Immunol; 2016 Feb; 196(3):1026-35. PubMed ID: 26729802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
    Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
    Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.